Literature DB >> 20854177

MicroRNAs as therapeutic targets for lung cancer.

William C S Cho.   

Abstract

Lung cancer is one of the leading causes of mortality in the world, indicating the need for innovative therapies for the disease. In recent years, microRNAs have emerged as one of the key players in regulating gene expression. Numerous studies have documented the implications of microRNAs in nearly every carcinogenesis process of lung cancer, including tumor development, apoptosis, invasion and metastasis, as well as anti-cancer drug resistance. Forced expression or suppression of microRNA can regulate the biological alteration during carcinogenesis, underscoring the therapeutic potential of microRNAs in lung cancer. This editorial summarizes recent reports of some key microRNAs that can modulate the lung cancer carcinogenesis process, expound the mechanisms by which they exert their functions, introduce some approaches for manipulating the action of microRNAs, and discuss the perspectives of microRNAs as therapeutic targets for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854177     DOI: 10.1517/14728222.2010.522399

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  10 in total

1.  Applications of MicroRNAs in the Diagnosis and Prognosis of Lung Cancer.

Authors:  Jun Shen; Feng Jiang
Journal:  Expert Opin Med Diagn       Date:  2012-05

2.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31

3.  Grand Challenges and Opportunities in Deciphering the Role of Non-Coding RNAs in Human Diseases.

Authors:  William C S Cho
Journal:  Front Genet       Date:  2011-01-19       Impact factor: 4.599

4.  Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis.

Authors:  William C S Cho
Journal:  Front Genet       Date:  2011-02-28       Impact factor: 4.599

5.  Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.

Authors:  Fengfeng Wang; Fei Meng; Sze Chuen Cesar Wong; William C S Cho; Sijun Yang; Lawrence W C Chan
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

6.  [Molecular diagnostics for monitoring and predicting therapeutic effect in cancer].

Authors:  William C S Cho
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-07

7.  Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in Non-Small Cell Lung Cancers in Iran.

Authors:  Bahareh Nourmohammadi; Elham Tafsiri; Amirabbas Rahimi; Zahra Nourmohammadi; Abolghasem Daneshvar Kakhaki; William Cho; Morteza Karimipoor
Journal:  Asian Pac J Cancer Prev       Date:  2019-06-01

8.  Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer.

Authors:  Alona Levy-Jurgenson; Xavier Tekpli; Vessela N Kristensen; Zohar Yakhini
Journal:  Sci Rep       Date:  2020-11-02       Impact factor: 4.379

9.  [Promises and challenges in developing MiRNA as a molecular diagnostic tool for lung cancer].

Authors:  William C S Cho
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-02

Review 10.  Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review.

Authors:  Shadab Md; Nabil A Alhakamy; Shahid Karim; Gamal A Gabr; Mohammad Kashif Iqubal; Samar S A Murshid
Journal:  Pharmaceutics       Date:  2021-12-08       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.